Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPM 502

Next Previous
X
Search
Drug Profile

TPM 502

Alternative Names: TPM-502

Latest Information Update: 07 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Topas Therapeutics
  • Class Peptides
  • Mechanism of Action Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Coeliac disease

Most Recent Events

  • 04 Jul 2024 Topas Therapeutics completes a phase-II clinical trial in Coeliac disease (In the elderly, In adults) in Australia, Finland, Germany, Netherlands, Norway, Sweden (IV) (NCT05660109) (EudraCT2022-001656-41)
  • 12 Dec 2022 Phase-II clinical trials in Coeliac disease (In the elderly, In adults) in Australia, Germany (IV) (NCT05660109) (EudraCT2022-001656-41)
  • 12 Dec 2022 Phase-II clinical trials in Coeliac disease (In adults, In the elderly) in Norway (IV) (NCT05660109) (EudraCT2022-001656-41)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top